Jana M. Ellegast
YOU?
Author Swipe
View article: Inflammatory signaling in the pathogenesis of acute myeloid leukemia
Inflammatory signaling in the pathogenesis of acute myeloid leukemia Open
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic stem and progenitor cells and the most common malignant myeloid disorder in adults. Extensive research has elucidated the broad spectrum of biological mechani…
View article: Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2
Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2 Open
Summary While the development of venetoclax with azacitidine (ven/aza) has improved AML therapy, drug resistance remains a major challenge. Notably, primary ven/aza-resistant AML are frequently reliant on MCL1, however, the underlying mech…
View article: Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia
Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia Open
CBFA2T3::GLIS2 fusion positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapeutic approaches in this disease subtype we performed genome-scale CRISPR-Cas9 sc…
View article: Pulmonary Hypertension in the Field of Hematological and Oncological Diseases
Pulmonary Hypertension in the Field of Hematological and Oncological Diseases Open
Introduction: Hematological and oncological diseases collectively affect a substantial number of patients. Pulmonary hypertension (PH) is recognized as a potential rare complication associated with these conditions, manifesting in various …
View article: Functional Dissection of Cellular Programs to Uncover Novel Gene Dependencies in AML
Functional Dissection of Cellular Programs to Uncover Novel Gene Dependencies in AML Open
Genome-scale CRISPR-Cas9 screens have the power to unveil the Achilles' heel of neoplastic cells. Typically, analyses of such large-scale data sets focus on single gene dependencies. An alternative strategy is to evaluate functional networ…
View article: PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy Open
PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely under…
View article: Supplementary Table from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Table from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Table from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Supplementary Table from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Table from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Table from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Data from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Data from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Leukemic blasts are immune cells gone awry. We hypothesized that dysregulation of inflammatory pathways contributes to the maintenance of their leukemic state and can be exploited as cell-intrinsic, self-directed immunotherapy. To this end…
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Data from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Data from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Leukemic blasts are immune cells gone awry. We hypothesized that dysregulation of inflammatory pathways contributes to the maintenance of their leukemic state and can be exploited as cell-intrinsic, self-directed immunotherapy. To this end…
View article: Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts Open
Supplementary Figure from Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
View article: Data from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Data from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechan…
View article: Supplementary Methods from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Supplementary Methods from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
Computational analysis methods for RNAseq, WES, synergy analyse, Masspec information used for phosphoproteomic studies.
View article: Supplementary Figures from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Supplementary Figures from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
Fig. S1: Characterization of effects of Entospletinib in AML in vitro and in vivo, Fig. S2: Genome-scale lentiviral ORFeome library screen identifies drivers of entospletinib resistance in AML.; Fig. S3: Viability analysis with increasing …
View article: Supplementary Figures from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Supplementary Figures from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
Fig. S1: Characterization of effects of Entospletinib in AML in vitro and in vivo, Fig. S2: Genome-scale lentiviral ORFeome library screen identifies drivers of entospletinib resistance in AML.; Fig. S3: Viability analysis with increasing …
View article: Supplementary Tables from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Supplementary Tables from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
IC50, pYome results in MV4-11 and MOLM14, ORF-Screen Data in MV4-11 and MOLM14 and merged hits, SNV indels and copy number alteration of MV4-11 naive and resistant cells
View article: Data from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Data from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechan…
View article: Supplementary Methods from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Supplementary Methods from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
Computational analysis methods for RNAseq, WES, synergy analyse, Masspec information used for phosphoproteomic studies.
View article: Supplementary Tables from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Supplementary Tables from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia Open
IC50, pYome results in MV4-11 and MOLM14, ORF-Screen Data in MV4-11 and MOLM14 and merged hits, SNV indels and copy number alteration of MV4-11 naive and resistant cells